Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02298348 · ClinicalTrials.gov registry record · Phase 1

Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma

A Phase 1 study of Neuroblastoma, sponsored by New Approaches to Neuroblastoma Therapy Consortium.

Active
Registry status
Phase 1
Development phase
18
Enrollment target
12
Study locations

NCT02298348 is a Phase 1 study of Neuroblastoma that is active but no longer recruiting, run by New Approaches to Neuroblastoma Therapy Consortium. The registered enrollment target is 18 participants, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (92% lower). The trial reports 12 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02298348, a Phase 1 study of Neuroblastoma, is active but no longer recruiting, sponsored by New Approaches to Neuroblastoma Therapy Consortium.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
18 participants
Enrollment target
12
Study locations

Study Summary

This study will combine three drugs: sorafenib, cyclophosphamide and topotecan. Adding sorafenib to cyclophosphamide and topotecan may increase the effectiveness of this combination. The investigators first need to find out the highest dose of sorafenib that can be given safely together with cyclophosphamide and topotecan. This is the first study to test giving these three drugs together and will help determine the highest dose of sorafenib that can safely be given together with cyclophosphamide and topotecan to patients with resistant/relapsed neuroblastoma.

Conditions Studied

Neuroblastoma

Interventions

  • DRUG Cyclophosphamide
  • DRUG Topotecan
  • DRUG Sorafenib

Study Locations (12)

California

  • Children's Hospital Los Angeles - Los Angeles
  • UCSF Comprehensive Cancer Center - San Francisco

Colorado

  • Children Hospital of Colorado - Aurora

Georgia

  • Children's Healthcare of Atlanta - Atlanta

Illinois

  • University of Chicago, Comer Children's Hospital - Chicago

Massachusetts

  • Childrens Hospital Boston, Dana-Farber Cancer Institute. - Boston

Michigan

  • C.S Mott Children's Hospital - Ann Arbor

North Carolina

  • University of North Carolina - Chapel Hill

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2015-10-08
Est. Completion 2026-12
Phase Phase 1

Sponsor

New Approaches to Neuroblastoma Therapy Consortium

23 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02298348

The ClinicalTrials.gov registry entry for NCT02298348 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (92% lower). The listed sponsor is New Approaches to Neuroblastoma Therapy Consortium, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.

NCT02298348 reports 12 study locations spanning 11 distinct geographic areas - top geographies include California, Colorado, Georgia.

Frequently Asked Questions

What is clinical trial NCT02298348 about?

NCT02298348 is a clinical study titled "Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma". This study will combine three drugs: sorafenib, cyclophosphamide and topotecan. Adding sorafenib to cyclophosphamide and topotecan may increase the effectiveness of this combination. The investigators first need to find out the highest dose of sorafenib that can be given safely together with cyclop...

What is the current status of trial NCT02298348?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2015-10-08. Estimated completion is 2026-12.

What conditions does trial NCT02298348 study?

This clinical trial studies the following conditions: Neuroblastoma.

What interventions are being tested in trial NCT02298348?

The interventions under investigation include: Cyclophosphamide (DRUG), Topotecan (DRUG), Sorafenib (DRUG).

Who is sponsoring clinical trial NCT02298348?

This trial is sponsored by New Approaches to Neuroblastoma Therapy Consortium, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02298348 being conducted?

This trial has 12 study locations across California, Colorado, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neuroblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neuroblastoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.